Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin in children and young adults with Prader-Willi syndrome
2013-004134-15Phase 3Completed
- Sponsor
- Dutch Growth Research Foundation
- Start
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing Oxytocin with Placebo (2 arms). Primary endpoint: Change in appetite, satiety, food intake, and social behavior after 4 weeks of oxytocin versus 4 weeks of placebo. Started Mar 2014; status: completed.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2013-004134-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004134-15.